Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker AZN · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 23, 2026 | SYMBICORT AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA216579 ↗ |
| Oct 21, 2026 | ULTOMIRIS RAVULIZUMAB-CWVZ | AZN Alexion Pharm | Biologic (BLA), supplement Efficacy | BLA761108 ↗ Letter or label ↗ |
| Oct 21, 2026 | SOLIRIS ECULIZUMAB | AZN Alexion Pharm | Biologic (BLA), supplement REMS | BLA125166 ↗ Letter or label ↗ |
| Oct 8, 2026 | BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE | AZN Astrazeneca AB | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220290 ↗ |
| Sep 23, 2026 | CRESTOR ROSUVASTATIN CALCIUM | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA021366 ↗ |
| Sep 16, 2026 | TRUQAP CAPIVASERTIB | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA218197 ↗ |
| Sep 14, 2026 | TAGRISSO OSIMERTINIB MESYLATE | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA208065 ↗ |
| Sep 14, 2026 | TAGRISSO OSIMERTINIB MESYLATE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA208065 ↗ |
| Sep 4, 2026 | ETCAMAH CAMIZESTRANT | AZN Astrazeneca | New drug (NDA) Type 1 - New Molecular Entity | NDA220359 ↗ |
| Aug 31, 2026 | IMJUDO TREMELIMUMAB-ACTL | AZN Astrazeneca AB | Biologic (BLA), supplement Labeling | BLA761289 ↗ |
| Aug 31, 2026 | IMFINZI DURVALUMAB | AZN Astrazeneca UK Ltd | Biologic (BLA), supplement Labeling | BLA761069 ↗ |
| Aug 11, 2026 | XIGDUO XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA205649 ↗ |
| Aug 11, 2026 | XIGDUO XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA205649 ↗ |
| Aug 11, 2026 | KOMBIGLYZE XR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA200678 ↗ |
| Aug 7, 2026 | SAPHNELO ANIFROLUMAB-FNIA | AZN Astrazeneca AB | Biologic (BLA), supplement Labeling | BLA761123 ↗ |
| Jun 30, 2026 | SOLIRIS ECULIZUMAB | AZN Alexion Pharm | Biologic (BLA), supplement Labeling | BLA125166 ↗ |
| Jun 12, 2026 | TRUQAP CAPIVASERTIB | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA218197 ↗ |
| Jun 3, 2026 | QTERN DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA209091 ↗ |
| Jun 3, 2026 | FARXIGA, DAPAGLIFLOZIN DAPAGLIFLOZIN | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA202293 ↗ |
| Jun 1, 2026 | ULTOMIRIS RAVULIZUMAB-CWVZ | AZN Alexion Pharm | Biologic (BLA), supplement REMS | BLA761108 ↗ Letter or label ↗ |
| Jun 1, 2026 | SOLIRIS ECULIZUMAB | AZN Alexion Pharm | Biologic (BLA), supplement REMS | BLA125166 ↗ Letter or label ↗ |
| May 28, 2026 | IMFINZI DURVALUMAB | AZN Astrazeneca UK Ltd | Biologic (BLA), supplement Efficacy | BLA761069 ↗ |
| May 27, 2026 | TRUQAP CAPIVASERTIB | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA218197 ↗ |
| May 26, 2026 | KOSELUGO SELUMETINIB; SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA219943 ↗ Letter or label ↗ |
| May 26, 2026 | KOSELUGO SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA213756 ↗ Letter or label ↗ |
| May 15, 2026 | BAXFENDY BAXDROSTAT | AZN Astrazeneca AB | New drug (NDA) Type 1 - New Molecular Entity | NDA219878 ↗ |
| May 13, 2026 | FASENRA BENRALIZUMAB | AZN Astrazeneca AB | Biologic (BLA), supplement Efficacy | BLA761070 ↗ |
| May 7, 2026 | BRILINTA TICAGRELOR | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA022433 ↗ |
| Apr 29, 2026 | CRESTOR ROSUVASTATIN CALCIUM | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA021366 ↗ |
| Apr 27, 2026 | SYMBICORT AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA216579 ↗ |
| Apr 27, 2026 | BREZTRI AEROSPHERE BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE | AZN Astrazeneca AB | New drug (NDA), supplement Efficacy | NDA212122 ↗ |
| Apr 24, 2026 | SAPHNELO ANIFROLUMAB-FNIA | AZN Astrazeneca AB | Biologic (BLA) Type 5 - New Formulation or New Manufac… | BLA761451 ↗ |
| Apr 15, 2026 | WAINUA EPLONTERSEN SODIUM | AZN Astrazeneca AB | New drug (NDA), supplement Efficacy | NDA217388 ↗ Letter or label ↗ |
| Apr 7, 2026 | BEYFORTUS NIRSEVIMAB-ALIP | AZN Astrazeneca AB | Biologic (BLA), supplement Labeling | BLA761328 ↗ |
| Feb 19, 2026 | CALQUENCE ACALABRUTINIB MALEATE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA216387 ↗ Letter or label ↗ |
| Feb 19, 2026 | CALQUENCE ACALABRUTINIB | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA210259 ↗ Letter or label ↗ |
| Dec 17, 2025 | WAINUA EPLONTERSEN SODIUM | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA217388 ↗ |
| Nov 25, 2025 | IMFINZI DURVALUMAB | AZN Astrazeneca UK Ltd | Biologic (BLA), supplement Efficacy | BLA761069 ↗ |
| Nov 19, 2025 | KOSELUGO SELUMETINIB; SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA219943 ↗ |
| Nov 19, 2025 | KOSELUGO SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA213756 ↗ |
| Nov 14, 2025 | TRUQAP CAPIVASERTIB | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA218197 ↗ |
| Oct 20, 2025 | BEYFORTUS NIRSEVIMAB-ALIP | AZN Astrazeneca AB | Biologic (BLA), supplement Efficacy | BLA761328 ↗ |
| Oct 17, 2025 | TEZSPIRE TEZEPELUMAB-EKKO | AZN Astrazeneca AB | Biologic (BLA), supplement Efficacy | BLA761224 ↗ |
| Sep 26, 2025 | ULTOMIRIS RAVULIZUMAB-CWVZ | AZN Alexion Pharm | Biologic (BLA), supplement Manufacturing (CMC) | BLA761108 ↗ |
| Sep 15, 2025 | AIRSUPRA ALBUTEROL SULFATE; BUDESONIDE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA214070 ↗ |
| Sep 10, 2025 | KOSELUGO SELUMETINIB; SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA) Type 3 - New Dosage Form | NDA219943 ↗ |
| Sep 10, 2025 | KOSELUGO SELUMETINIB SULFATE | AZN Astrazeneca | New drug (NDA), supplement Efficacy | NDA213756 ↗ |
| Sep 2, 2025 | BYETTA EXENATIDE SYNTHETIC | AZN Astrazeneca AB | New drug (NDA), supplement Labeling | NDA021773 ↗ |
| Jul 10, 2025 | LYNPARZA OLAPARIB | AZN Astrazeneca | New drug (NDA), supplement Labeling | NDA208558 ↗ |
| Jun 27, 2025 | VOYDEYA DANICOPAN | AZN Alexion Pharmaceuticals Inc | New drug (NDA), supplement REMS | NDA218037 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:05 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates